Cartilage Repair and Regeneration Market Growth is attributed to the Increased Prevalence of Joint and Bones Disorders

Cartilage Repair and Regeneration Market Overview:

The cartilage repair and regeneration market size was valued at USD 1,523.7 million in 2022 and is poised to grow at a 12.8% CAGR from 2023 to 2029.  The availability of advanced technologies in imaging, diagnostics, and surgical methods for better visualization and treatment planning for cartilage repair with minimal invasion, and individualized treatment plans drives the market. Furthermore, the rise in public awareness about available treatment options for cartilage injuries that can provide long-term relief and improved quality of life is also anticipated to propel the market growth. The increased geriatric population and increase in injuries among sports players have also led to a tremendous surge in market demand. The availability of options for personalized medicine with the advancements in genetics and molecular biology tailored according to patient treatment requirements and doctor’s opinions has opened up opportunities for market development among the manufacturers. Additionally, the development of advanced biomaterials to provide mechanical support, cell adhesion, and controlled release of growth factors, to enhance the regenerative process and improve treatment has gained popularity in the market. For instance, Nanochon developed Chondrograft, a 3D-printed biomaterial that is on an FDA premarket approval pathway and has started human clinical trials in the summer of 2023 and anticipates gaining approval for market launch by 2027. 

The cartilage repair and regeneration market report is segmented based on types of cartilage, treatment modality, treatment type, application, and geography.

Based on the types of cartilage, the market is segmented into the following:

• Fibrocartilage
• Hyaline Cartilage
• Elastic Cartilage
• Others

Based on the treatment modality, the market is segmented into the following:

• Cell-based
  • Chondrocyte Transplantation
  • Stem Cells
  • Growth Factors
• Non-cell-based
  • Tissue Scaffolds
  • Cell-free Composites

Based on the treatment type, the market is segmented into the following:

• Palliative
• Intrinsic Repair Stimulus

Based on the application, the market is segmented into the following:

• Knee
• Spine
• Ankle
• Hip
• Others

Based on the surgical procedure, the market is segmented into the following:

• Chondroplasty and Microfracture
• Autologous Chondrocyte Implantation
• Osteochondral Autograft Transplantation
• Osteochondral Allograft Transplantation
• Juvenile Allograft Fragment
• Others

Based on the end-user, the market is segmented into the following:

• Ambulatory Care Centres
• Hospitals and Clinics
• Surgical Centres
• Others

The Hyaline Cartilage Segment Dominates the Cartilage Repair and Regeneration Market:

Based on the types of cartilage, hyaline cartilage dominates the industry and is anticipated to show a significant growth rate over the forecasting period. The high vulnerability of hyaline cartilage to damage in the event of cartilage-related accidents and the rise in sports-related injuries that lead to anomalies in the articular cartilage of the knee and other joints is anticipated to encourage sector expansion. Furthermore, the rise in physical trauma incidents around the world, that could cause patients to acquire osteochondral and chondral lesions is also anticipated to propel the market during the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 199,800 Americans die from injuries that are deadly each year. Throughout the projection period, it is predicted that there will be an increase in both fatal and nonfatal injuries, which will help the market expand.

Based on Geography, the market is segmented into the following:

• North America
• Europe
• Asia Pacific
• Latin America
• MEA 

North America Leads Cartilage Repair and Regeneration Market:

North America accounted for a significant share in the global infectious diagnostics market. The market is expected to grow at a significant CAGR over the forecast years owing to United States and Canada having large number of incidents of cartilage damage, and osteoporosis. According to Office of Disease Prevention and Health Promotion (ODPHP), in United States, an estimated 10 million people age 50 years and older have osteoporosis. Asia Pacific is also anticipated to grow in the forecasting period owing to a rise in cases of diabetes and cartilage injuries in China, Japan, and India. According to IDF Diabetes Atlas 10th edition reports, South East Asia has 90 million and Western Pacific has 206 million cases of diabetes. Furthermore, the rising incidence of cartilage damage in Australia and New Zealand due to osteoporosis is expected to foster the development of this region. 

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:

Cartilage repair and cartilage regeneration market further reveals that the key players increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

• In June 2023, Anika Therapeutics, Inc. completed its pivotal Phase III clinical study for its knee cartilage repair product, HyaloFast® (HyaloFast 15-01).
• In March 2022, CartiHeal Ltd, a developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee joints, received approval from the U.S. Food and Drug Administration (FDA) for its Agili-C™ implant.

The cartilage repair and regeneration market report key players are Osiris Therapeutics, Inc. (U.S.), Smith + Nephew (U.K.), AlloSource (U.S.), Vericel Corporation (U.S.), Zimmer Biomet (U.S.), Medtronic (Ireland), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), B. Braun SE (Germany), Orthocell Ltd. (Australia), Geistlich Pharma AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), CONMED Corporation (U.S.), The Future of Biotechnology, MEDIPOST (South Korea), BioTissue (U.S.), LifeNet Health (U.S.), RTI Surgical  (U.S.) and Arthrex, Inc. (Germany).